BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Closing Bell: The risk-trade back on (AIG, GENZ, NLST, GE, CMCSA, KMP)]]>http://www.bloggingstocks.com/2009/12/01/closing-bell-the-risk-trade-back-on-aig-genz-nlst-ge-cmcsa/http://www.bloggingstocks.com/2009/12/01/closing-bell-the-risk-trade-back-on-aig-genz-nlst-ge-cmcsa/http://www.bloggingstocks.com/2009/12/01/closing-bell-the-risk-trade-back-on-aig-genz-nlst-ge-cmcsa/#commentsFiled under: , , ,

Many said that today was based on solid economic data, but the markets were already pointed handily north. Today was about traders putting the risk trade back on by buying stocks and buying commodities. Dubai's explosive consequences seem to be mitigated, but that will be determined in time.

Here were the unofficial closing bell levels today:

Dow 10,471.58 +126.74 (1.23%)
S&P 500 1,108.86 +13.23 (1.21%)
Nasdaq 2,175.81 +31.21 (1.46%)

Top Day Trader Alerts
Top 10 Analyst Calls
Top Stock Rumors

Continue reading Closing Bell: The risk-trade back on (AIG, GENZ, NLST, GE, CMCSA, KMP)

Closing Bell: The risk-trade back on (AIG, GENZ, NLST, GE, CMCSA, KMP) originally appeared on BloggingStocks on Tue, 01 Dec 2009 16:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AIGalicocerezymeCMCSAGEGENZKMPNLSTTue, 01 Dec 2009 16:20:00 EST<![CDATA[Genzyme's Cerezyme shortage may cause more problems than anticipated]]>http://www.bloggingstocks.com/2009/07/10/genzymes-cerezyme-shortage-may-cause-more-problems-than-anticip/http://www.bloggingstocks.com/2009/07/10/genzymes-cerezyme-shortage-may-cause-more-problems-than-anticip/http://www.bloggingstocks.com/2009/07/10/genzymes-cerezyme-shortage-may-cause-more-problems-than-anticip/#commentsFiled under:

Pharmaceutical drugmaker Genzyme (NASDAQ: GENZ), based in Cambridge, Massachusetts, specializes in creating drugs for rare diseases. Despite the small market, the Orphan Drug Act gives the company tax credits and enhanced patent protection, virtually guaranteeing that its drugs become blockbusters, like it's Gaucher's disease drug Cerezyme.

Recently, the company has halted production of the drug after a virus was discovered in production equipment at its Allston plant. Since the company expects a shortage in the supply of the drug, Genzyme said it would ask some consumers to conserve their stocks of the drug by temporarily skipping or reducing doses. The missed doses will not cause significant health problems, Genzyme said.

Continue reading Genzyme's Cerezyme shortage may cause more problems than anticipated

Genzyme's Cerezyme shortage may cause more problems than anticipated originally appeared on BloggingStocks on Fri, 10 Jul 2009 14:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>CerezymeGauchers diseaseGauchersDiseasegenzgenzymeinthenewsFri, 10 Jul 2009 14:20:00 EST